Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportGeneral Clinical Specialties

Old tracer for new purpose: Tc-99m-2-methoxyisobutylisonitril (Tc-99m-MIBI) for imaging nephrotoxicity

S. Dizdarevic, Mark Aplin, S. Holt, Lawrence. Goldberg, K. Miles and A. Peters
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 596;
S. Dizdarevic
1Brighton and Sussex University Hospitals, Brighton, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Aplin
1Brighton and Sussex University Hospitals, Brighton, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Holt
1Brighton and Sussex University Hospitals, Brighton, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence. Goldberg
1Brighton and Sussex University Hospitals, Brighton, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
K. Miles
2Brighton and Sussex Medical School, Brighton, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Peters
2Brighton and Sussex Medical School, Brighton, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

596

Objectives Tc-99m-MIBI is a P-glycoprotein (P-gp) substrate used for in vivo imaging of P-gp-related multidrug resistance. P-gp, an ATP-binding cassette (ABC) transporter protein, promotes the cellular efflux of cyclosporine, tacrolimus and other potentially nephrotoxic drugs. The only known mechanism of Tc-99m-MIBI elimination from renal tubular cells involves ABC transporter proteins, so Tc-99m-MIBI kinetics may indicate renal P-gp status. Some patients constitutionally express low levels of P-gp, encoded by the mdr1 gene, and may require lower doses of immuno-suppressants. The study aims were to image P-gp expression and also demonstrate that differential renal function (DRF), based on Tc-99m-MIBI, is similar to, and could replace, Tc-99m-MAG3 DRF.

Methods Thirty healthy kidney transplant donors were dynamically imaged for 20 min after injection of 400 MBq Tc-99m-MIBI. Static 5-min images were acquired at 30 and 120 min. Bland-Altman analysis was used to assess agreement between DRF based on Tc-99m-MIBI and Tc-99m-MAG3. The rate constants (k) of Tc-99m-MIBI elimination from kidney, liver, spleen and myocardium were calculated from count rates recorded at 30 and 120 min.

Results Tc-99m-MIBI and Tc-99m-MAG3 showed different patterns of renal handling but good agreement with respect to DRF. k showed no difference between liver (0.0048 [SD 0.0011] min-1) and spleen (0.00414 [0.000829] min-1; p=0.096) but was lower in the kidney (0.00225 [0.000835] min-1; p<0.001) and myocardium (0.00094 [0.000546] min-1; p<0.001). There were significant correlations between k values of all 4 tissues (R2=0.27-0.36).

Conclusions DRF can be accurately measured with Tc-99m-MIBI. The tissue elimination rates of Tc-99m-MIBI give measures of constitutional P-gp expression. All 4 organs have some level of P-gp expression, the myocardium the lowest. Tc-99m-MIBI may provide useful information regarding dose selection of nephrotoxic drugs that are P-gp substrates

Back to top

In this issue

Journal of Nuclear Medicine
Vol. 53, Issue supplement 1
May 2012
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Old tracer for new purpose: Tc-99m-2-methoxyisobutylisonitril (Tc-99m-MIBI) for imaging nephrotoxicity
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Old tracer for new purpose: Tc-99m-2-methoxyisobutylisonitril (Tc-99m-MIBI) for imaging nephrotoxicity
S. Dizdarevic, Mark Aplin, S. Holt, Lawrence. Goldberg, K. Miles, A. Peters
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 596;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Old tracer for new purpose: Tc-99m-2-methoxyisobutylisonitril (Tc-99m-MIBI) for imaging nephrotoxicity
S. Dizdarevic, Mark Aplin, S. Holt, Lawrence. Goldberg, K. Miles, A. Peters
Journal of Nuclear Medicine May 2012, 53 (supplement 1) 596;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

General Clinical Specialties

  • Exploring variations and utility of FDG- and NaF PET/CT in rheumatoid arthritis and osteoarthritis
  • Application of Lung perfusion only scan combined with SPECT/CT for the post-treatment evaluation of massive and sub-massive pulmonary embolism in the age of covid-19 pandemic: case presentation and literature review
  • Can FDG PET/CT imaging have a role in clinical cases of Dermatomyositis?
Show more General Clinical Specialties

Renal Scintigraphy

  • Evaluation of recovery of native renal function in patients with hepatorenal syndrome following combined liver and kidney transplant. Is kidney transplant necessary?
  • Diagnosis of acute rat renal allograft rejection with 18F-FDG labeled T-lymphocytes and positron emission tomography
  • Technetium-99m Pertechnetate imaging in the diagnosis of peritoneal leaks in peritoneal dialysis
Show more Renal Scintigraphy

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire